Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aclaris Therapeutics (ACRS) has provided an update.
Andrew Powell has informed Aclaris Therapeutics of his decision to step down from the board, coinciding with the 2024 Annual Meeting on June 6. Additionally, Bryan Reasons will not seek re-election to the board once his term ends at the same meeting. Both departures are independent of any disputes over the company’s operations, policies, or practices.
For a thorough assessment of ACRS stock, go to TipRanks’ Stock Analysis page.